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Abstract
Protein intake robustly stimulates the secretion of the incretin hormone, glu-
cagon-like peptide-1 (GLP-1) but the molecular mechanisms involved are not
well understood. In particular, it is unknown whether proteins stimulate secre-
tion by activation of luminal or basolateral sensors. We characterized the
mechanisms using a physiologically relevant model – the isolated perfused
proximal rat small intestine. Intraluminal protein hydrolysates derived from
meat (peptone; 50 mg/mL) increased GLP-1 secretion 2.3-fold (from a basal
secretion of 110  28 fmol/min). The sensory mechanisms underlying the
response depended on di/tripeptide uptake through Peptide Transporter 1
(PepT1) and subsequent basolateral activation of the amino acid sensing
receptor, Calcium-Sensing Receptor (CaSR), since inhibition of PepT1 as well
as CaSR both attenuated the peptone-induced GLP-1 response. Supporting
this, intraluminal peptones were absorbed efficiently by the perfused intestine
(resulting in increased amino acid concentrations in the venous effluent) and
infusion of amino acids robustly stimulated GLP-1 secretion. Inhibitors of
voltage-gated L-type Ca2+ channels had no effect on secretion suggesting that
peptone-mediated GLP-1 secretion is not mediated by L-cell depolarization
with subsequent opening of these channels. Specific targeting of CaSR could
serve as a target to stimulate the endogenous secretion of GLP-1.
Introduction
The incretin hormone, glucagon-like peptide-1 (GLP-1) is
an important regulator of glucose homeostasis as it
strongly potentiates glucose-induced insulin secretion,
inhibits gastric emptying, and lowers food intake (Baggio
and Drucker 2007; Holst 2007). Because of these effects,
GLP-1 is an attractive target for the treatment of both
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type 2 diabetes and obesity, and GLP-1-based drugs are
now used for both indications (Zander et al. 2002;
Drucker and Nauck 2006; Pi-Sunyer et al. 2015). An
alternative approach for targeting the GLP-1 axis for
treatment of type 2 diabetes and obesity, which has
gained increasing interest and recognition, is to selectively
activate the secretory machinery of the GLP-1-secreting L
cell. This strategy may prove to be superior to GLP-1
receptor agonists or DPP-4 inhibitors for two reasons: (1)
Part of the insulinotropic and appetite-inhibiting effect of
GLP-1 is thought to be caused by the activation of vagal
afferents in the intestinal mucosa (immediately after its
release), and this pathway may not be accessible for the
GLP-1 enhancers or analogues (Furness et al. 1999; Holst
and Deacon 2005; Steinert 2011), (2) Targeting the L-cell
secretion may also, at least to some extent, lead to
increased secretion of colocalizing hormones including
peptide YY (PYY), neurotensin, oxyntomodulin, and glu-
cose-dependent insulinotropic polypeptide (GIP), which
inhibit appetite and/or are insulinotropic (Svendsen et al.
2015). Targeting L-cell secretion, however, requires
detailed knowledge of the molecular mechanisms that
trigger secretion and although progress has been made,
many details are still missing.
Ingested proteins are among the most powerful stimuli
for GLP-1 secretion in humans (Elliott et al. 1993; Hall
et al. 2003; Raben et al. 2003; van der Klaauw et al. 2013)
but the sensing mechanisms are not well characterized. In
vivo and in vitro studies have pointed to a role for Pep-
tide Transporter 1 (PepT1), a proton-coupled di/tripep-
tide transporter, in peptide-triggered GLP-1 secretion
(Matsumura et al. 2005; Diakogiannaki et al. 2013;
Dranse et al. 2018). A mechanism involving the H+-cou-
pling of PepT1 transport, leading to membrane depolar-
ization (indirectly through sodium, as the protons
instantly will be transported out of the cell again through
a Na+/H+ exchanger) and calcium influx through L-type
voltage-gated calcium channels has been proposed (Mat-
sumura et al. 2005). In addition, several amino acids (the
final digestive product of proteins) have been demon-
strated to stimulate GLP-1 secretion in various experi-
mental models (Herrmann et al. 1995; Reimann et al.
2004; Greenfield et al. 2009; Tolhurst et al. 2011; Pais
et al. 2016); however, our understanding of the underly-
ing molecular pathways is generally incomplete but sug-
gested mechanisms include activation of amino acid
sensing G-protein-coupled receptors (Calcium-Sensing
Receptor (CaSR) and Umami Taste Receptor (T1R1/
T1R3), GPRC6A) (Mace et al. 2012; Diakogiannaki et al.
2013; Pais et al. 2016). Most importantly, it is unknown
whether amino acids or di- and tripeptides stimulate
secretion before, during or after intestinal absorption, or
in other words, whether secretion is caused by activation
of luminal, intracellular, or basolateral sensors. Given that
protein digestion generates a mixture of breakdown prod-
ucts, ranging from large oligopeptides to smaller di/
tripeptides and individual amino acids, the ability to
sense protein digestion products is likely to involve sev-
eral stimulation pathways. To characterize the molecular
mechanisms responsible for protein-stimulated GLP-1
secretion, we performed a series of experiments on iso-
lated perfused rat small intestine, stimulating the prepara-
tion with intraluminal peptones while key candidate
sensors/transporters were activated or inhibited by selec-
tive compounds.
Materials and Methods
Ethical considerations
Studies were carried out with permission from the Danish
Animal Experiments Inspectorate (2018-15-0201-01397)
and the local ethics committee (EMED, P18-336). All
experiments were performed in accordance with the
guidelines of Danish legislation governing animal experi-
mentation (1987) and the National Institutes of Health.
Animals
Male Wistar rats (200–250 g) were obtained from Janvier
(Le Genest-Saint-Isle, France), and housed two per cage
and kept on a 12-h light/dark cycle with free access to
water and standard chow. Rats were acclimatized for at
least a week.
Perfusion of the proximal small intestine
At the day of experiment, nonfasted rats were anes-
thetized with a subcutaneous injection of Hypnorm/
Midazolam and placed on a 37°C heated operating plate.
When lack of reflexes was established, the operation was
started by opening of the abdominal cavity. The vascular
supply to colon was ligated and the colon was carefully
removed. The small intestine was divided into its proxi-
mal and distal half. The vascular supply to the distal half
was ligated so that only the proximal half was perfused
(35 cm, CV = 13.6%). A plastic tube was placed in the
lumen of the proximal jejunum and the intestinal con-
tents were carefully removed by flushing with prewarmed
(37°C) isotonic saline. Throughout the experimental pro-
tocol, a constant luminal flow of heated saline (37°C) was
applied (0.25 mL/min) via a syringe pump. A catheter
was inserted into the superior mesenteric artery and the
intestine was vascularly perfused with heated perfusion
buffer (37°C) at a constant flow rate of 7.5 mL/min. A
metal catheter was inserted into vena portae to collect the
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venous effluent. Rats were euthanized by perforation of
the diaphragm as soon as proper flow was apparent. As
an indicator of the health of the intestine, perfusion pres-
sure was continuously monitored. To allow for equilibra-
tion of the system, the intestine was perfused for 25 min
before initiation of the experimental protocol. The venous
effluent was collected for 1 min periods via the draining
catheter using a fraction collector. The samples were
immediately chilled on ice and stored at 20°C until
analysis. The procedure is described in more detail else-
where (Kuhre et al. 2015).
Perfusion protocol and test substances
Each protocol started with a 10-min baseline period of
luminal saline (0.9% NaCl) infusion followed by addition
of various test substances to either the luminal or arterial
side of the preparation. Vascular infusion of test sub-
stances was carried out (at an infusion rate of 0.375 mL/
min) for 5–15 min periods (indicated in the results sec-
tion). Luminally applied test substances were adminis-
tered for 15-min periods at an initial rate of 0.5 mL/min
for the first 2 min (to replace saline solution in the
lumen) followed by 0.25 mL/min throughout the remain-
ing stimulation period. Immediately after each stimula-
tion period, the lumen was flushed with a similar bolus
of isotonic saline (0.5 mL/min for 2 min), followed by
infusion at a flow rate of 0.25 mL/min (baseline). Bombe-
sin (10 nmol/L; BBS), a known GLP-1 secretagogue, was
infused at the end of each experiment as a positive con-
trol for hormone responses.
All test substances were purchased from Sigma-Aldrich
(Brøndby, Denmark): peptone, cat. no. P5905; glycyl-sar-
cosine, cat. no. G3127; nifedipine, cat. no. N7634; 4-(ami-
nomethyl)benzoic acid, cat. no. 283746; calindol
hydrochloride, cat. no. SML1386; bombesin, B4272; and
NPS2143 hydrochloride, cat. no. SML0362. Test stimuli
applied to the luminal side of the gut were diluted in iso-
tonic saline, whereas compounds applied to the vascular
side were diluted in perfusion buffer (PB). PB was a
Krebs-Ringer bicarbonate buffer supplemented with 0.1%
(w/v) bovine serum albumin (cat. no. 1.12018.0500,
Merck Ballerup, Denmark), 5% (w/v) dextran T-70
(Pharmacosmos, Holbaek, Denmark), 3.5 mmol/L glu-
cose, and 5 mmol/L of each pyruvate, fumarate, and glu-
tamate (Sigma Aldrich, Broendby, Denmark). Prior to
every experiment, a mixture of amino acids, Vamin (cat.
no.11338, Fresenius-kabi, Uppsala Sweden), was added
(2 mL/L) to the PB along with 10 lmol/L 3-isobutyl-1-
methylxanthine (IBMX) (cat no. 5879, Sigma Aldrich).
The PB was filtered (at 0.25 lm) to remove potential par-
ticles/precipitates and the pH was adjusted to 7.4–7.5.
Before entering the organ, the PB was heated to 37°C and
gassed with a mixture of 95% O2 and 5% CO2 to maxi-
mally increase the oxygen concentration and ensure a pH
of 7.4.
Hormone and L-amino acid analysis
GLP-1 concentrations in venous effluents were measured
by an in house radioimmunoassay. An antiserum directed
against the amidated C-terminus of GLP-1 (code no.
89390) was used, allowing measurement of total amidated
GLP-1. I125-labeled GLP-1 7-36NH2 (a gift from Novo
Nordisk A/S, Bagsværd, Denmark) was used as a tracer.
Hormone concentrations were calculated by interpolation
to a GLP-1 standard curve set up in perfusion buffer
using synthetic GLP-1 7-36NH2 (H-6795-GMP; Bachem).
The experimental detection limit was 1 pmol/L and the
coefficient of variation was <6% at 20 pmol/L.
Amino acid concentrations in venous effluents were
measured using a colorimetric L-amino acid assay kit
from Abcam (cat. no. ab65347, Cambridge, UK), follow-
ing the provided protocol. Reportedly, the assay detects
all L-amino acids but glycine with a sensitivity of
40 lmol/L.
Quantification and statistical analysis
Hormone outputs were calculated by multiplying perfu-
sion flow (7.5 mL/min) with the GLP-1 concentration in
the effluent (measured in pmol/L). Hormone outputs are
presented as mean values  SEM. Statistical calculations
were performed using GraphPad Prism 7 software (La
Jolla, CA, USA). To test for statistical significance of
responses, GLP-1 outputs within the test period (10 min)
were compared after subtraction of baseline GLP-1 out-
puts (calculated over 10 min preceding test substance
administration). Student’s t-test and one-way ANOVA for
repeated measurements followed by Bonferroni post hoc
test were used as indicated in the results section. P-values
<0.05 were considered statistically significant.
Results
Luminal peptone stimulates GLP-1 secretion
from the proximal small intestine
Luminal infusions of peptone derived from meat (50 mg/
mL) stimulated GLP-1 secretion in double administration
control experiments (Fig. 1A). Both infusions (P1 and
P2) increased GLP-1 secretion approximately twofold
compared to baseline GLP-1 secretion (B1 and B2) (B1:
110  28 fmol/min vs. P1: 256  58 fmol/min, P < 0.05,
B2: 122  26 fmol/min vs. P2: 211  36 fmol/min,
P < 0.05, n = 6) (Fig. 1B).
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Since peptone is a mixture of enzymatically generated
peptide fragments, both free amino acids and oligopep-
tides are present in the peptone mixture. To separate the
relative contributions of free amino acids and di/tripep-
tides, we stimulated the intestines in separate experiments
with a dipeptide resistant to luminal degradation; Glycyl-
Sarcosine (Gly-Sar; 22 mg/mL), as well as a mixture of 18
different amino acids (not including glutamine), Vamin,
administered intraluminally as well as intra-arterially
(Fig. 1C+1E). Luminally infused Gly-Sar (G1) increased
GLP-1 secretion almost twofold compared to baseline
(B1) (B1: 108  32 fmol/min vs. G1: 196  40 fmol/
min, P < 0.05, n = 6) (Fig. 1D). In addition, both lumi-
nally (V1) and vascularly (V2) infused amino acids (51
and 4.25 mg/mL, respectively) increased GLP-1 secretion
with luminal amino acids increasing GLP-1 levels 2.6-fold
compared to baseline secretion (B1) (B1: 143  32 fmol/
min vs. V1: 380  173 fmol/min, P < 0.05, B2:
160  35 fmol/min vs. V2: 282  59 fmol/min,
P = 0.2235, n = 6) (Fig. 1F). This indicates that both free
amino acids and dipeptides may contribute to the pep-
tone-induced GLP-1 release.
Since the GLP-1 response to luminal amino acids may
be secondary to amino acid absorption, we measured the
concentration of amino acids in the venous effluent
before and after stimulation with luminal-infused amino
acids (Fig. 1G). The luminal stimulus increased the total
amino acid concentration in the venous effluent 2.3-fold
compared to baseline (B1aa: 1336  239 lmol/L vs. V1aa:
3088  501 lmol/L, P < 0.05, n = 6) (Fig. 1H), showing
that luminal amino acids are rapidly absorbed and trans-
ported to the vascular side of the gut.
Blockage of PepT1 inhibits peptone-
stimulated GLP-1 secretion and peptide
absorption
To study whether absorption of peptides via PepT1 is
important for peptone-stimulated GLP-1 secretion, we
blocked PepT1-mediated uptake with the nontranslocated
competitive inhibitor, 4-aminomethyl benzoic acid (4-
AMBA; 20 mmol/L), while stimulating the intestine with
luminal peptones. This resulted in elimination of the pep-
tone-mediated GLP-1 response (Fig. 2A, n = 6), demon-
strating that uptake via PepT1 is essential for the
peptone-mediated GLP-1 secretion. When subtracting
baselines, GLP-1 secretion in response to the second pep-
tone stimulation was much lower after 4-AMBA adminis-
tration, compared to the response to the second peptone
stimulation in control experiments (P2: Fig. 1A; sub-
tracted baseline) (P2: 90  36 fmol/min vs. P24-AMBA:
14  28 fmol/min, P < 0.05, n = 6) (Fig. 2B).
To test whether peptides absorbed by PepT1 are
degraded to amino acids and transported to the vascular
supply in our experimental model, we measured the total
amino acid concentration in the venous effluent following
stimulation with luminal peptones. As expected, the con-
centration of (total) amino acids increased robustly and
quickly following peptone administration (B1aa:
1340  122 lmol/L vs. P1aa: 1995  129 lmol/L,
P < 0.05, n = 6, B2aa: 1370  163 lmol/L vs. P2aa:
1772  201 lmol/L, P < 0.05, n = 6) (Fig. 2C; black
curve). However, since the increase in amino acids in the
venous effluent could arise from the uptake of free amino
acids present in the peptone mixture, rather than from
absorption of di- and tripeptides, we next blocked PepT1
and administered intraluminal peptones (Fig. 2C; red
curve). In these experiments, 4-AMBA abolished the rise
in vascular amino acids during the second peptone stimu-
lation (P2aa) (baseline-subtracted values; P2aa:
402  156 lmol/L vs. P2aa+4-AMBA: 38  62 lmol/L,
P < 0.05, n = 6) (Fig. 2D), demonstrating that PepT1 is
crucial for the absorption of di- and tripeptides.
However, since the peptone-induced increase in vascu-
lar amino acids derived almost completely from the
uptake of di/tripeptides, as opposed to the uptake of
free amino acids present in the peptone mixture
(Fig. 2C+D), the specificity of 4-AMBA as a PepT1
blocker was tested in control experiments, where amino
acids (Vamin; 51 mg/mL) were infused intraluminally,
while PepT1 was blocked with 4-AMBA (20 mmol/L)
(Fig. 2E; red curve). The amount of amino acids in the
Figure 1. Luminal peptone stimulates GLP-1 secretion from the proximal small intestine. (A) Total GLP-1 outputs shown as means  SEM.
Peptone (50 mg/mL) was infused intraluminally between minute 11–25 and minute 46–60. Bombesin (BBS; 10 nmol/L), a positive control, was
infused between minute 80–85. (B) Mean GLP-1 outputs at baseline (Baseline 1 and 2) and following stimulation with luminal peptones
(Peptone 1 and 2). (C) Total GLP-1 outputs shown as means  SEM. Gly-Sar (22 mg/mL) was infused intraluminally between minute 11–25 and
minute 46–60 (D) Mean GLP-1 outputs at baseline (baseline 1 and 2) and following stimulation with luminal Gly-Sar (Gly-Sar 1 and 2). (E) Total
GLP-1 outputs shown as means  SEM. Vamin (51 mg/mL) was infused intraluminally between minute 11–25. Vamin (4.25 mg/mL) was
infused intravascularly between minute 46–60. (F) Mean GLP-1 outputs at baseline (baseline 1 and 2) and following stimulation with luminal
and vascular Vamin, respectively. (G) Total amino acid concentrations in venous effluent shown as means  SEM. (H) Mean concentrations of
total amino acids at baseline (baseline 1 and baseline 2) and following stimulation with, respectively, luminally and vascularly administered
Vamin. Statistical significance was tested by one-way ANOVA for repeated measurements followed by Bonferroni post hoc test; NS:
nonsignificant: P > 0.05. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. n = 6 for all groups.
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venous effluent was measured (V2aa+4-AMBA; Fig. 2F) and
compared to a Vamin double administration control
experiment (Fig. 2E; black curve) (V2aa; Fig. 2F). In
these experiments, 4-AMBA inhibited the rise in vascular
amino acids during luminal Vamin stimulation (base-
line-subtracted values; V2aa: 1291  749 lmol/L vs.
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V2aa+4-AMBA: 184  81 lmol/L, P < 0.05, n = 4–6,
Fig. 2F), demonstrating that 4-AMBA is probably not
fully specific for PepT1, but also blocks the uptake of
free amino acids present in the intestinal lumen.
L-type Ca2+-channels are not involved in
peptone-stimulated GLP-1 secretion
To examine whether the mechanism of peptone-mediated
secretion involved depolarization of the L cells and open-
ing of voltage-gated (L-type) Ca2+ channels as a result of
proton-coupled uptake of di/tripeptides by PepT1 (and
sodium-coupled uptake of free amino acids) or other
sodium-coupled transporters, we inhibited the L-type
Ca2+-channels with nifedipine (10 lmol/L) while stimu-
lating the intestine luminally with peptone. Nifedipine
was infused intra-arterially, beginning 5 min prior to
stimulation with peptones, to ensure that the channels
were fully inhibited at the time of peptone administration
(Fig. 3A).
Nifedipine did not reduce the peptone-mediated GLP-1
response when compared with the responses observed in
the peptone double-stimulation control experiment (P2:
Fig. 1A; subtracted baseline) (P2: 90  36 fmol/min vs.
P2nif: 93  64 fmol/min, P = 0.9191, n = 6) (Fig. 3B).
Furthermore, in control experiments, nifedipine did not
affect the Gly-Sar-mediated GLP-1 secretion when
compared to the second response in a Gly-Sar double
control experiment (G2; Fig. 1C) (baseline-subtracted val-
ues; G2: 57  36 fmol/min vs. G2nif:39  24 fmol/min,
P = 0.4219, n = 4–6, Fig. 3C+D), indicating that PepT1
does not mediate GLP-1 secretion by depolarization-
dependent mechanisms.
To validate that the lack of effect of nifedipine was not
related to bio-inactivity or concentration-related issues,
we tested whether nifedipine inhibited glucose-stimulated
GLP-1 secretion, which has been demonstrated by several
research groups (including our own) to be driven by the
opening of L-type Ca2+ channels (secondary to by electro-
genic uptake of glucose via sodium-glucose cotransporter
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Figure 3. L-type Ca2+-channels are not involved in peptone-stimulated GLP-1 secretion. (A) Total GLP-1 outputs shown as means  SEM.
Peptone (50 mg/mL) was intraluminally infused between minute 11–25 and minute 46–60. Nifedipine (10 lmol/L), an L-type Cav
2+-channel
inhibitor, was infused intravascularly between minute 40–60. (B) Mean values of the baseline-subtracted peptone-stimulated GLP-1 outputs
with and without nifedipine (Peptone 2; Fig. 1 vs. Peptone 2 + nifedipine). (C) Total GLP-1 outputs shown as means  SEM. Gly-Sar (22 mg/
mL) was intraluminally infused between minute 11–25 and minute 46–60. Nifedipine (10 lmol/L) was infused intravascularly between minute
40–60. (D) Mean values of the baseline-subtracted Gly-Sar-stimulated GLP-1 outputs with and without nifedipine (Gly-Sar 2; Fig. 1 vs. Gly-Sar
2 + nifedipine). Statistical significance was tested by an unpaired student’s t-test; NS: nonsignificant: P > 0.05. *P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.0001. n = 6 for all groups except Gly-Sar + nifedipine, n = 4.
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1 (SGLT1)). Nifedipine (10 lmol/L) strongly inhibited
the second glucose-induced GLP-1 response (baseline-
subtracted values; Glucose2: 227  40 fmol/min vs. Glu-
cose2nif: 91  17 fmol/min, P < 0.05, n = 4, data not
shown).
Calcium-Sensing Receptor is located on the
basolateral membrane and is involved in
peptone-mediated GLP-1 secretion
Since our balance of evidence suggested that absorption of
protein digestion products is the main driver of peptone-
induced GLP-1 secretion (Fig. 2), and since peptides are
rapidly transported to the vascular side of the gut in the
form of amino acids (Fig. 2C), we next investigated the
role of a well-known amino acid sensing receptor, CaSR,
in peptone-stimulated GLP-1 secretion. To establish
whether CaSR played a role for GLP-1 secretion in general,
we initially stimulated the perfused intestine with a specific
positive allosteric modulator of CaSR, calindol (50 lmol/
L), luminally and vascularly. Calindol strongly stimulated
GLP-1 secretion when infused vascularly (Cvasc), but had
marginal and nonsignificant effects on secretion when
administered luminally at the same concentration (Clum)
(B1: 133  40 fmol/min vs. Clum: 158  50 fmol/min,
P > 0.9999, B2: 195  56 fmol/min vs. Cvasc:
380  68 fmol/min, P < 0.05, n = 6) (Fig. 4A+B). Our
data therefore suggest that CaSR is located on the basolat-
eral side, and could be involved in the secretory GLP-1
response to vascular amino acids.
To validate the specificity of calindol as a CaSR agonist,
we examined whether we were able to inhibit the vascular
response with a negative allosteric modulator of CaSR,
NPS2143. NPS2143 (25 lmol/L), inhibited the vascular
calindol-induced (50 lmol/L) GLP-1 response signifi-
cantly, supporting the claimed specificity of calindol (B1:
143  35 fmol/min vs. calindol: 321  37 fmol/min,
P < 0.05, B2: 162  44 fmol/min vs. calindol+NPS2143:
201  24 fmol/min, P = 0.8946, n = 4, Fig. 4C+D).
To investigate the involvement of CaSR in the peptone-
stimulated GLP-1 secretion, we next stimulated the perfused
intestine with luminal peptones, while inhibiting CaSR with
NPS2143 (25 lmol/L) (Fig. 4E). This inhibited the second
peptone-induced GLP-1 response (P2: Fig. 1A) signifi-
cantly, when subtracting baselines (P2: 90  36 fmol/min
vs. P2+NPS2143: 47  10 fmol/min, P < 0.05, n = 6)
(Fig. 4F), indicating that CaSR is involved in the sensing of
absorbed protein digestion products.
Discussion
GLP-1 is secreted from L cells in the gastrointestinal tract
upon meal intake. The products of digestion contributing
to GLP-1 release include glucose and fructose, fatty acids,
and in particular 2-monoacylglycerols, amino acids, and
oligopeptides (Orskov et al. 1991; Tolhurst et al. 2009;
Hansen et al. 2012; Kuhre et al. 2014). The mechanisms
by which carbohydrates are sensed by the L cells have
been relatively well characterized, and include electrogenic
sugar (glucose, galactose) uptake by the sodium-depen-
dent glucose transporter 1 (SGLT1), possibly in conjunc-
tion with the metabolism of glucose and closure of ATP-
sensitive K+-channels (Gorboulev et al. 2012; Parker et al.
2012; R€oder et al. 2014; Kuhre et al. 2015) but the mech-
anisms by which ingested fat and protein trigger GLP-1
release are less well characterized.
In particular, it was not established whether protein
and/or amino acids stimulate secretion by activation of
luminal or basolateral sensors. As this cannot be investi-
gated in isolated cell systems (because of the inherent loss
of cell polarization in cultured cells) and is difficult to
investigate in vivo (because control of luminal vs. basolat-
eral exposure is difficult to achieve), we investigated the
molecular mechanisms of peptone-stimulated GLP-1
secretion using isolated perfused rat small intestines. With
this preparation, luminal and vascular exposure to a given
stimulus can be strictly controlled and the gut performs
in many aspects as it does in vivo: it respires, absorbs
Figure 4. Calcium-Sensing Receptor is located on the basolateral membrane and is involved in peptone-mediated GLP-1 secretion. (A) Total
GLP-1 outputs shown as means  SEM. Calindol (50 lmol/L), a positive allosteric modulator of CaSR, was intraluminally infused between
minute 11–25 and intravascularly infused between minute 51–65. (B) Mean GLP-1 outputs at baseline (Baseline 1 and 2) and following
stimulation with luminal calindol and vascular calindol. (C) Total GLP-1 outputs shown as means  SEM. Calindol (50 lmol/L) was
intraluminally infused between minute 11–25 and intravascular infused between minute 51–65. NPS2143 (25 lmol/L), a negative allosteric
modulator of CaSR, was intravascularly infused between minute 41–60. (D) Mean GLP-1 outputs at baseline (Baseline 1 and 2) and following
stimulation with vascular calindol (Calindol 1) and calindol + NPS2143 (Calindol 2 + NPS2143). (E) Total GLP-1 outputs shown as
means  SEM. Peptone (50 mg/mL) was intraluminally infused between minute 11–25 and 51–65. NPS2143 (25 lmol/L), was intravascularly
infused between minute 41–60. (F) Mean values of baseline-subtracted peptone-stimulated GLP-1 secretion with and without NPS2143
(Peptone 2; Fig. 1 vs. Peptone 2 + NPS2143). Statistical significance was tested by one-way ANOVA for repeated measurements followed by
Bonferroni post hoc test (Fig. 4B+D) and by unpaired student’s t-test (Fig. 4F); NS: nonsignificant: P > 0.05. *P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.0001. n = 6 for all groups except Calindol + NPS2143 (Fig. 4C), n = 4.
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nutrients, and has preserved polarization and preserved
vascular and nerve supply (Svendsen and Holst 2016;
Kuhre et al. 2017), and importantly, it is possible to
follow the full dynamic spectrum of secretion, minute for
minute. Furthermore, as a consequence of adequate vas-
cular perfusion, both absorptive and secretory processes
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can proceed without inhibition by accumulating sub-
strates or products. Using this model, we found that pep-
tone-stimulated GLP-1 secretion is highly dependent
upon absorption of smaller peptides and amino acids in
the proximal rat small intestine. Our findings suggest that
basolateral sensing of amino acids, produced as a result
of intracellular digestion of di/tripeptides, may be the
most important mechanism by which L cells sense and
react to ingested protein (Fig. 5). This was supported by
our finding that amino acids powerfully stimulated GLP-
1 secretion also from the vascular side, and that luminally
infused protein digestion products were rapidly absorbed
as reflected by a rise in vascular amino acids (Fig. 2C+D).
However, the molecular mechanisms underlying amino
acid stimulated GLP-1 secretion are complex and proba-
bly dependent on activation of different molecular sensors
by the individual amino acid. For instance, glutamine,
which has been shown to raise plasma GLP-1 levels in
humans (Greenfield et al. 2009), is thought to stimulate
GLP-1 secretion through activation of two different path-
ways. One involves membrane depolarization through
electrogenic Na+-coupled uptake and another involves
elevation of intracellular cAMP levels, the details of which
remain unclear (Reimann et al. 2004; Tolhurst et al.
2011). The depolarization would lead to opening of vol-
tage-gated calcium channels with intracellular calcium
increases leading to exocytosis of the hormone. This path-
way should be sensitive to blockade of the v-gated
Ca2+ v
AA
Na+ H+
K Na+
ATP
Amino acids
Amino acids
Di/tripeptides
CaSR
Amino acids
PLC
IP3
Ca2+
GLP-1 SecretionBlood
Lumen
Na+ H Peptide
H Peptide
ψ
Figure 5. Illustration of the endocrine L cell and the proposed mechanisms by which peptone stimulates GLP-1 release. Di/tripeptides are taken
up by PepT1 and are degraded by cytosolic peptidases to their respective amino acids. In addition, free amino acids present in the intestinal
lumen may be taken up by different amino acid transporters. Intracellular amino acids are then transported to the interstitial side through
basolateral amino acid transporters, wherefrom they stimulate the L cells by activating amino acid sensors, like CaSR, situated on the
basolateral membrane.
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calcium channels with nifedipine. Indeed, this was
observed in a study of the effect of peptones on cultured
small intestinal epithelial cells (Pais et al. 2016) but in the
present study, nifedipine had no effects on peptone-
induced secretion. The difference might be due to differ-
ent amino acid composition of the peptones applied, but
might also derive from the use of a random mixture of
isolated cells (which may influence secretion of each
other) as opposed to our use of an intact, polarized
epithelium. In contrast, the importance of the voltage-
gated calcium channels was clearly illustrated in our
experiments by the strong inhibitory effect of nifedipine
on glucose-stimulated GLP-1 secretion, which clearly
involves depolarization by sodium cotransported with
glucose. Further experiments with single amino acids
thought to be transported together with sodium will
hopefully clarify this.
Another sensor that has been suggested to be involved
in protein-stimulated GLP-1 secretion is CaSR, which is
highly expressed in GLP-1 secreting L cells (Diakogian-
naki et al. 2013). Activation of this receptor has been
demonstrated to stimulate GLP-1 secretion in several
studies of mixed primary mouse mucosal cell cultures
(Diakogiannaki et al. 2013; Pais et al. 2016; Alamshah
et al. 2017). CaSR is predominantly Gq-coupled, leading
to calcium release from intracellular stores (Conigrave
and Ward 2013). CaSR is activated by a wide range of L-
amino acids with the aromatic amino acids being the
most potent agonists (Conigrave et al. 2000; Conigrave
and Hampson 2006). However, structural studies suggest
that CaSR is also able to bind oligopeptides (Wang et al.
2006). Importantly, to date, it was unknown whether api-
cal or basolateral activation of CaSR mediates peptone-
stimulated GLP-1 secretion, as previous studies (in vitro
or in vivo) were unable to discriminate between these.
Here, we demonstrate that basolateral rather than luminal
activation of CaSR mediates the response, since blockage
of receptor activity from the vascular side (by NPS2143)
inhibited the peptone-induced secretory response, and
since infusion of a CaSR-specific agonist stimulated GLP-
1 secretion only from the vascular side.
A limitation of our study is that in all our experiments
with either peptone or Vamin, the second GLP-1 response
was lower than the first albeit the amount of absorbed
amino acids was similar during both stimulations. The
relatively short washing period in between the two stimu-
lations (20 min) could explain this, as the molecular sen-
sors involved may have been saturated/desensitized by the
first stimulation by the time of the second stimulation.
More specifically, the CaSR may have been desensitized
or internalized during/after the first stimulation. Support-
ing this, two similar GLP-1 responses were observed in a
glucose double control experiment (Glu1: 487  77 fmol/
min vs. Glu2: 434  57 fmol/min, P > 0.9999, n = 4,
data not shown), demonstrating that the lower second
GLP-1 response seen is not due to a general reduced via-
bility of the organ by the time of the second stimulation
period but instead seems to depend on the stimulatory
compound and the signaling pathway involved. This
could likewise explain the lower GLP-1 response seen
after infusion of vascular amino acids compared to infu-
sion of luminal amino acids (Fig. 1E+F), as the amino
acid sensors may have been internalized/desensitized after
the first stimulation period with luminally infused amino
acids. Moreover, the PepT1 blocker used in this study (4-
AMBA) appeared not to be specific for di/tripeptide
uptake but also blocked the uptake of free amino acids in
the intestinal lumen. Although we were not able to distin-
guish between the uptake of free amino acids and di/
tripeptides, when stimulating with peptone, our study
clearly demonstrated that absorption of both digestion
products is essential for protein-stimulated GLP-1 secre-
tion in the proximal rat small intestine, since addition of
4-AMBA eliminated the peptone-induced GLP-1
response.
The contribution of individual amino acids to total
peptone-stimulated GLP-1 secretion, and the respective
molecular pathways involved, awaits further investigation.
Key sensors to be investigated are: GPRC6A, T1R1/T1R3,
GPR142, GPR93, and GPR35, although the importance of
GPRC6A was recently questioned (Clemmensen et al.
2017). In addition, how Gly-Sar stimulates GLP-1 secre-
tion deserves further exploration, as the mechanism is
currently unclear. It is possible that Gly-Sar stimulate sen-
sors on the basolateral side as a dipeptide, similar to
amino acids.
In conclusion, our data indicated that proteins stimulate
GLP-1 secretion through absorbed amino acids, which
activate amino acid sensing receptors, including CaSR, sit-
uated on the basolateral membrane (Fig. 5). As mentioned
in the introduction, therapies based on stimulation of the
endogenous secretion of L-cell products (as seen after gas-
tric bypass operations) might be beneficial compared to
the administration of exogenous hormones, and for this a
detailed knowledge of the stimulatory mechanisms is
essential. In this respect, stimulation with proteins is of
particular interest in view of their robust effect on secre-
tion and appetite (Elliott et al. 1993; Weigle et al. 2005;
Belza et al. 2013; van der Klaauw et al. 2013). Currently,
the effects of oral amino acid supplementation on GLP-1
secretion in humans have been variable (Nilsson et al.
2007; Greenfield et al. 2009; Lindgren et al. 2015; Trico
et al. 2018), and therefore warrants further clarification.
The essential CaSR is expressed in many tissues of the
body (kidneys, gut, parathyroid gland) and agonism may
therefore have many effects, but oral administration
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of absorbable agonists might preferentially stimulate
intestinal receptors. The robust stimulation of GLP-1
secretion observed in the current experiments supports
further investigations into protein-induced secretion.
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